{"id":251122,"date":"2024-01-05T00:00:00","date_gmt":"2024-01-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0018-biopharma-pulmonary-hypertension-epidemiology-mature\/"},"modified":"2026-04-14T10:16:18","modified_gmt":"2026-04-14T10:16:18","slug":"epidcv0018-biopharma-pulmonary-hypertension-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0018-biopharma-pulmonary-hypertension-epidemiology-mature-markets\/","title":{"rendered":"Pulmonary Hypertension &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of pulmonary hypertension (<abbr title=\"pulmonary hypertension\">PH<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of <abbr title=\"pulmonary hypertension\">PH<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the remaining countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"pulmonary hypertension\">PH<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed <abbr title=\"pulmonary hypertension\">PH<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"pulmonary hypertension\">PH<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"pulmonary hypertension\">PH<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"pulmonary hypertension\">PH<\/abbr> by subtype.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"6187\" title=\"pulmonary arterial hypertension\">PAH<\/abbr> by etiology.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"6187\" title=\"pulmonary arterial hypertension\">PAH<\/abbr> by New York Heart Association (<abbr title=\"New York Heart Association\">NYHA<\/abbr>) severity classification scheme.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"pulmonary hypertension\">PH<\/abbr> associated with left-heart disease (<abbr title=\"left heart disease\">LHD<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"pulmonary hypertension\">PH<\/abbr> associated with <abbr title=\"left heart disease\">LHD<\/abbr> by etiology subtype.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"pulmonary hypertension\">PH<\/abbr> associated with chronic lung disease.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"pulmonary hypertension\">PH<\/abbr> associated with chronic lung disease by comorbid lung condition.<\/li>\n<li>Diagnosed prevalent cases of chronic thromboembolic pulmonary hypertension (<abbr title=\"chronic thromboembolic pulmonary hypertension\">CTEPH<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic thromboembolic pulmonary hypertension\">CTEPH<\/abbr> by surgical intervention.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"pulmonary hypertension\">PH<\/abbr> caused by miscellaneous factors.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"pulmonary hypertension\">PH<\/abbr> by drug treatment.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251122","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-hypertension","biopharma-therapy-areas-pulmonary-hypertension","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251122\/revisions"}],"predecessor-version":[{"id":293492,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251122\/revisions\/293492"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}